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02 The Journal of Thoracic and Cardiobjective: The study objective was to find a mitral valve substitute that does not
equire lifelong anticoagulation and is not affected by tissue degeneration in the long
erm.
ethods: Between July 14, 1997, and August 8, 2004, a total of 92 patients with
rreparable mitral valve disease underwent mitral valve replacement with the pul-
onary autograft encased within a Dacron tubing for support. In 4 patients, the
utograft had to be sacrificed at the initial operation. Of the remaining 88 patients,
2 were female, and the age ranged from 4 to 64 years (mean 39 years). Eighty-six
atients had rheumatic mitral disease, and 2 patients had congenital mitral disease.
esults: Operative transesophageal echocardiography initially showed adequate
alve characteristics (mean valve area 2.8 cm2, mean gradient 3.9 mm Hg, no
ignificant regurgitation) in all 88 patients. Operative mortality was 4.6%, and late
ortality definitely related to the operation was 7.9%. Four patients were lost to
ollow-up; the mean follow-up was 60 months. Progressive regurgitation and
tenosis developed in 9 patients over 2 to 5 years, 4 of whom had their grafts
xplanted. The autograft was explanted in 1 patient because of endocarditis. Mild
ulmonic stenosis developed in 3 patients, and critical pulmonic stenosis developed
n 1 patient. At 5 years follow-up, freedom from degeneration was 93.4%, freedom
rom reoperation was 94.2%, and freedom from all death was 86.0%.
onclusion: Although the Ross II operation is difficult and harbors significant risk,
t remains an option for patients with irreparable mitral disease who have a long life
xpectancy and who cannot be placed on lifelong anticoagulation.
n an effort to find an optimal mitral valve substitute for patients with rheumatic
mitral disease that does not require the lifelong anticoagulation necessary for
mechanical valves and resists the expected outcome of degeneration of heter-
graft and homograft valves, we started to revive the Ross concept of substituting
he inverted pulmonary autograft for the excised mitral valve in 1997.1 In this
ndeavor we hoped to achieve for the mitral valve what has already been accom-
lished for the aortic valve.2 This study is an analysis of the outcome o
ulmonary autografts implanted in the mitral position during a 7-year period, ending
n August of 2004.
aterials and Methods
etween July 14, 1997, and August 8, 2004, a total of 92 consecutive patients with irreparable
itral valve disease underwent mitral valve replacement with the pulmonary autograft (Ross
I operation) by the same surgical team at Damascus University Cardiovascular Surgical
enter.
Because of a temporary lack of pulmonary homografts and xenografts, as well as a
recipitous decrease in available mitral candidates, we were unable to perform this procedure
or approximately 8 months after August 8, 2004. After this date, the operation was resumed
vascular Surgery ● October 2007
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CDn a sporadic basis as allowed by patients’ availability. In this
eport we present the analysis of our first 92 patients, because they
elonged to a single time frame.
Exclusion criteria were significant aortic valve disease, pulmo-
ary artery systolic pressure greater than 90 mm Hg, previous
ardiac operation or pericardial adhesions found at operation,
nnular mitral calcification, and ejection fraction less than 30%.
The mitral pulmonary autograft had to be sacrificed during the
nitial operation in 4 of the 92 patients, so the total number of
atients reviewed was 88.
The male-to-female ratio was 26:62, and the patients were aged
etween 4 and 64 years, with a mean of 39.2 years (11.2 years).
igure E1 depicts the age distribution according to 10-year gr
Eighty-six patients had rheumatic mitral disease, and 2 patients
ad congenital mitral lesions (a parachute mitral valve in 1 patient
nd bileaflet mitral prolapse in 1 patient). Thirty-five patients had
redominant mitral stenosis, 42 patients had combined mitral
tenosis and regurgitation, and 11 patients had pure mitral regur-
itation. Twenty-six patients had, in addition, significant degrees
2/4) of tricuspid regurgitation, and 41 patients had insignificant
1.5/4) aortic regurgitation. Fifty patients were in atrial fibrilla-
ion, and 38 patients were in sinus rhythm. Twenty-eight patients
nderwent cardiac catheterization to rule out coronary artery dis-
ase. Most patients (81) were in New York Heart Association
lasses II and III, and preoperative echocardiography showed a
ean left atrial size of 6.0 cm. Table E1 shows some 
reoperative echo/Doppler data.
Every effort was made to repair the mitral valve before a
ecision on the operation was made. Carpentier’s principles of
itral repair3 were strictly adhered to. The ratio of patients a-
lly undergoing the Ross II procedure to those undergoing the
peration with the intent of performing it in case the mitral valve
as found irreparable was 1 to 3.
Details of the operation were described in a previous rep4
he operation in principle involves encasing the pulmonary au-
ograft within a Dacron tubing of appropriate size for support
efore suturing its distal (pulmonary) end to the excised mitral
alve annulus.
All operations were conducted under cardiopulmonary bypass,
oderate hypothermia, and blood cardioplegia. In the early stages
f our experience we favored a transseptal approach, but lately we
ave relied on a standard left atriotomy, except when the left
trium is small (5 cm).
Once the mitral valve was found beyond repair and a decision
as made to operate, the pulmonary artery was taken down and
eplaced with a suitable tissue substitute, as in the classic Ross
peration. Twenty-nine cryopreserved pulmonary homografts, 56
ulmonary xenografts (Ross, CryoLife, Inc, Kennesaw, Ga), and 3
ryopreserved aortic homografts were used for pulmonary trunk
eplacement.
While the surgeon replaced the pulmonary artery, the co-
Abbreviation and Acronym
TEE transesophageal echocardiographyurgeon inserted the trimmed pulmonary autograft inside a piece of t
The Journal of Thoraciche
igid Dacron tubing and sewed the proximal and distal ends to the
ubing edges, guided by premarked lines. The size of the Dacron
ubing was chosen to be slightly larger than the eye-balled size of
he pulmonary artery (a 1-inch long piece of size 30-mm tubing
as used in most patients). In the 2 children with congenital mitral
esions, the tubing was slit (along 1 side in 1 patient and along 2
ides in 1 patient) to allow for mitral annular growth with the
rowth of the child. The mitral valve was excised, preserving as
uch of the native subvalvular apparatus as possible, and the left
trial appendage was excluded.
Since December of 2002, microwave ablation (AFx, Inc, Fre-
ont, Calif) has been used in all of our patients with mitral disease
nd atrial fibrillation.5 Eleven patients in this series had at
brillation ablation. The distal end of the autograft/Dacron conduit
as finally sutured to the mitral annulus, the tricuspid valve was
epaired if necessary, and the atriotomy was closed. Intraoperative
ransesophageal echocardiography (TEE) was obtained when the
eart resumed its activity to ensure that results were acceptable
efore decannulation and chest closure.
We chose to place the pulmonary autograft conduit in the
trium rather than the ventricle because the design of the inverted
ulmonary autograft does not lend itself to having its distal (pul-
onary truck) end sutured to the papillary muscles, as is the case
ith the mitral homograft. Further, if most of the autograft/Dacron
ubing is placed in the ventricle it is bound to cause some left
entricular outflow obstruction, as was found in the early experi-
ents replacing the mitral valve with the pulmonary-autograft or
ortic homograft, before Hubka6 introduced the concept of placin
he conduit completely in the left atrium.
The “Achilles heel” of this operation has been conduit obstruc-
ion in some patients because of the angulation of the soft tubing
aterial, necessitating immediate reoperation for correction or
e-replacement. This potential problem has been managed in a
ariety of ways over the years.7-9
In the first 36 patients, a pericardial patch was used to anchor
he proximal edge of the autograft/Dacron conduit to the adjacent
trial wall (“top-hat” configuration), at the same time covering
oreign material and creating, in essence, a new left atrial floor, a
ethod originally advocated by Yacoub and Kittle.10 Because this
ethod did not seem to prevent Dacron tubing collapse, as we
ccidentally found out, and it became obvious to us that the
rmness of the Dacron material played a major role in preventing
he iatrogenic atrioventricular obstruction, we began using peri-
ardium simply to cover foreign material as a “miniskirt” to save
perative time and decrease operative risk.4 We also avoided
odern soft varieties of Dacron and adhered to using the original
esilient Dacron tissue when it was available, or autoclaving the
oft varieties with albumin when it was not, to give them the
equired resilience. After 10 patients we abandoned the use of
ericardium altogether to simplify the operation even further.
inally, because we were having difficulty obtaining old-fashioned
acron tubings, and because there was kinking of the Dacron
ubing even after autoclave treatment with albumin in 2 patients
possibly because the albumin coating dissolved later in warm
lood), we returned to the “miniskirt” pericardial configuration.
We now use the “miniskirt” pericardial configuration4 using
urgical glue (Bio Glue, CryoLife Inc, Kennesaw, Ga) in between
he Dacron cloth and the pericardial tissue. This seems to give the
and Cardiovascular Surgery ● Volume 134, Number 4 903
cp
Figur
E
p rativ
4
e
m
a
a
r
o
p
(
t
c
f
e
t
c
e
R
I
a
(
t
p
t
b
r
p
4
w
a
r
a
w
D
i
c
o
f
lists
t
m
h
i
c
o  on
d
i
a
m
(
f
p
b
p
u
e
n
a
c
d
c
m
d
o
i
t
p
r
I
G
t
v
t
t
b
T
M
H
C
d
c
c
Surgery for Acquired Cardiovascular Disease Kabbani et al
9
A
CDonduit the firm texture required and has solved the potential
roblem of mitral obstruction.
Table E2 shows the details of the operation in this series. 
2, A to O, depicts the various stages of the operation as we now
erform it. Figure E3 shows the Dacron conduit in a postope
-chamber view echocardiogram and a typical 2-dimensional
chocardiogram with color Doppler.
Follow-up with echocardiography was scheduled 1, 3, and 6
onths after the operation and yearly afterward. Patients were
nticoagulated for 3 months after the procedure, after which the
nticoagulant was discontinued, except for those patients who
emained in atrial fibrillation and an international normalized ratio
f 2 to 2.5 was sought. It has also been our policy to administer
enicillin prophylaxis at least until the patient is 40 years old.
Analyses were performed with Intercooled STATA version 9
StataCorp, College Station, Tex) and the Statistical Package for
he Social Sciences version 14 (SPSS Inc, Chicago, Ill). Survival
urves were done using Kaplan–Meier in the Statistical Package
or the Social Sciences version 14 (SPSS Inc). Autograft degen-
ration was designated as such when the mitral valve area was less
han 1.5 cm2 and/or when regurgitation was more than 1.5/4 (1.5
orresponding to mild regurgitation). The mitral regurgitation was
stimated by jet size and mental 3-dimensional jet reconstruction.
esults
ntraoperative TEE showed acceptable-to-excellent valve
reas (1.9–4.5 cm2; mean 2.76  0.45) and gradients
1.5–9 mm; mean 2.86  0.6), and 0-trace mitral regurgi-
ation (1.5/4) in 86 patients. However, in 6 of the total 92
atients, starting with our 33rd case, a significant obstruc-
ion was detected by intraoperative TEE, which was caused
y the shift from using old-fashioned Dacron tubing mate-
ial to using modern soft tubing material. In 2 of these
atients the problem was corrected at reexploration,7 but in
patients the autograft had to be explanted and replaced
ith a mechanical valve (bioprostheses were not available
t our unit at the time). All 4 patients who underwent
e-replacement of the autograft with mechanical prostheses
re presently well. The problem of acute autograft stenosis
as resolved with the use of surgical glue between the
acron cloth and the pericardial wrap and has not recurred
n our last 42 patients. Atrial fibrillation spontaneously
hanged to sinus rhythm postoperatively in 10 patients, and
f 11 patients who had microwave ablation, 8 were success-
ully converted to sinus rhythm.
Hospital mortality was 4.5% (4 patients). Table 1 
he causes of mortality and major hospital events. The
edian intensive care unit stay was 2 days, and the median
ospital stay was 7 days. There was 1 major hospital wound
nfection. The estimated pulmonary artery pressure on dis-
harge from the hospital was 12 to 60 mm Hg with a mean
f 27.4  9.5. Table E3 shows the echo/Doppler findings
ischarge from the hospital, which mimicked the findings of
ntraoperative TEE. A
04 The Journal of Thoracic and Cardiovascular Surgery ● Octoe
e
Four patients were lost to follow-up because of change of
ddress. The mean follow-up period was 60 months. Late
ortality totaled 11 patients. Two died of early endocarditis
within 2 months of operation) suspected to have originated
rom nosocomial attacks that affected our unit at the same
eriod their operations were performed. One patient died of
leeding at reoperation for paravalvular leak injury to the
ulmonary homograft. Two fatalities (of septicemia from
rinary tract infection, and excessive vomiting and severe
lectrolyte imbalance from gastroenteritis) were apparently
ot related to the operation per se, and 2 more patients died
t home 3 and 5 years after the operation without obvious
auses, although they were well when last seen. One patient
ied of hemopericardium brought about by excessive anti-
oagulation, 1 patient died of congestive heart failure after
yocardial infraction, and 2 patients died of late endocar-
itis. No autopsy could be obtained on the patient who died
f congestive heart failure.
Events during follow-up that were successfully managed
ncluded 1 late wound infection, 1 late pericarditis with
amponade, 3 episodes of major arrhythmia, and 1 major
aravalvular leak that was repaired.
Nine patients showed evidence of progressive autograft
egurgitation and/or stenosis, developing over 2 to 5 years.
n 4 of these patients, the autografts had to be explanted.
ross examination of the explants showed the valve leaflets
o be thickened and retracted in some cases. There were
ariable degrees of calcification, but no vegetations or
hrombi. Microscopically, explanted valves showed neoin-
ima formation (pannus), fibrosis, disruption of elastic fi-
ers, and scant and focal nonspecific chronic inflammation.
ABLE 1. Mortality and hospital events
No. of patients
ortality 4/88 (4.5%)
CVA 1
ARDS 1
Bleeding 1
Acute renal failure 1
ospital event
MI 2 (1 requiring IABP)
Low CO 1 (requiring IABP)
Bleeding 3
AV dissociation (temporary) 5
AF (temporary) 3
PPS 3
Paravalvular leak (minor) 3
Repair of flail pericardial collar 1
VA, Cerebrovascular accident; ARDS, acute respiratory distress syn-
rome; MI, myocardial infarction; IABP, intraaortic balloon pumping; CO,
ardiac output; AV, atrioventricular; AF, atrial fibrillation; PPS, post-peri-
ardiotomy syndrome.ctive rheumatic disease was suspected in 1 valve. The
ber 2007
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CDutograft was explanted in 1 patient because of endocarditis
years after the operation. There was no predilection of 1
f the 3 operative configurations to infection when com-
ared with the others.
Various degrees of pulmonic stenosis developed in 4
atients’ pulmonary xenograft (3) or homograft (1) during
he follow-up period. Only 1 patient (homograft, 5 years
ostoperative) now has significant (gradient  60 mm Hg)
tenosis and is awaiting reoperation.
A review of the 64 patients who are presently being
ollowed up (Table E4) shows that most are in sinus rh
ot taking anticoagulants, and in New York Heart Associ-
tion functional class I or II. Three patients who were in
trial fibrillation were not receiving anticoagulation because
here was a contraindication for it in 1 patient (in whom a
ubarachnoid hemorrhage developed) and noncompliance in
patients. The 3 patients received antiplatelet therapy. The
chocardiographic findings of the 64 patients (Table 
re, for the most part, acceptable.
Figure 1 depicts the freedom from valve degenera
urve, estimated at 93.4% after 5 years. Figure 2 depic
reedom from reoperation curve, estimated at 94.2% after 5
ears. Figure 3 depicts the general survival (freedom 
ll death) curve for the series, estimated at 86.0% after 5
ears. On exclusion of operative deaths, there were 2 fatal-
ties at the end of the first year, 4 fatalities at the end of the
econd year, 6 fatalities at the end of the third year, 9
atalities at the end of the fourth year, and 11 fatalities at the
nd of the fifth year. The 4 explant operations performed
ecause of Dacron tubing collapse were not taken into
igure 1. Actuarial freedom from valve degeneration in “success-
ul” Ross II procedures. N  number of patients included in the
nalysis at the beginning of each year follow-up.ccount in our calculations because we believe this problem
The Journal of Thoracic,
e
as adequately solved and will not be a factor in future
valuations.
We found no statistically significant differences in sur-
ival, reoperation, and degeneration outcomes across age
ategories; however, in multiple regression analysis, after
djustment for weight, height, and echocardiogram findings,
igure 2. Actuarial freedom from reoperation in “successful”
oss II procedures. N  number of patients included in the
nalysis at the beginning of each year follow-up.
igure 3. Actuarial survival curve in “successful” Ross II proce-
ures. N  number of patients included in the analysis at the
eginning of each year follow-up.and Cardiovascular Surgery ● Volume 134, Number 4 905
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CDnly age showed a strong negative relation with reoperation
P  .05) and mortality (P  .02).
Analysis of the 3 operative techniques showed no
tatistically significant differences in the outcomes of
eath, degeneration, and reoperation. The use of Bio-
lue did not produce ill effects in any of the patients, and
one of the patients in whom we used Bio-Glue under-
ent reoperation.
For the 4 patients who were lost to follow-up, the sur-
ival, degeneration, and reoperation curves show the events
n all patients up to the 5-year point when the software
xcluded the patients lost to follow-up from the analysis.
iscussion
he fact that an ideal mitral substitute has so far eluded
ardiac surgeons should not deter us from continued efforts
o solve this international problem.11 There is no questio
hat if mitral pathology can be corrected with reconstructive
urgery, that option should be exercised, even if the pathol-
gy is rheumatic; for there is no mitral valve better than
ne’s own. Not every valve, however, can be repaired, and
ftentimes a patient with a reconstructed rheumatic valve
eturns with a failed repair caused by recurrent rheumatic
ctivity. Choosing the right mitral substitute for a particular
atient is one of the most difficult decisions a cardiac
urgeon working in a developing country has to make. In
any of those countries proper anticoagulation is almost an
mpossibility,12 which makes mechanical prostheses, dur-
le as they are, undesirable. In regard to tissue options,
itral homografts are not used by their original proponents
ecause of lack of durability,13 and although the results 
he quadrileaflet bovine valve (Quattro, St Jude Medical Inc,
inneapolis, Minn) are good at midterm,14 it is still no
ommercially available.
Stented bioprostheses have not demonstrated suffi-
ient durability in young patients.15 Although the new
enerations of bioprostheses have fared much better, they
tart to degenerate quickly after their fifth year, espe-
ially in young patients.16-18 A comparison of our resul
ith the results of second-generation bioprostheses (eg,
arpentier–Edwards supra-annular porcine [Edwards
ifesciences, Irvine, Calif], Carpentier-Edwards Peri-
ount pericardial [Edwards Lifesciences], Hancock II
ioprosthesis [Medtronic, Inc, Minneapolis, Minn], and
iocor porcine bioprosthesis [St Jude Medical, St Paul,
inn]) failed to show a statistical difference in survival
r structural valve deterioration at 5 years. However,
ecause the mitral-pulmonary autograft is made of viable
utogenic tissue, we expect that it will be more durable in
he long run and be comparable to the pulmonary au-
ograft in the aortic position. Some of the early autografts
mplanted by Ross19 were functioning well 11 to 15 ye
fter the initial operation. i
06 The Journal of Thoracic and Cardiovascular Surgery ● OctoComparison of our reoperation (Figure E4) and surv
Figure E5) curves with those of the Ross registry (w
ossregistry.com) showed no statistically significant diff
nce in either case.
Rheumatic heart disease is still rampant in many parts of
he world and does not seem to be abating anytime so20
hildren, young adults, and expectant mothers who need
heir mitral valves replaced are entitled to an option better
han the mechanical valve, with its inherent thromboem-
olic risks and required taxing and relatively expensive
ifelong anticoagulation, and the available biologic valves,
ith their insufficient long-term durability.
There have been some reservations with regard to using
he Ross procedure in patients with rheumatic mitral dis-
ase.21,22 However, Al-Halees and colleagues21 concluded
hat it was inadvisable to offer the Ross operation to rheu-
atic patients with dilated aortic roots (28 mm) or to
atients with concomitant mitral valve disease.21 Kumar
nd colleagues22 added the factor of age (30 years), bu
his seems to be a point of contention (see “Discussion” in
umar and colleagues’ article). Despite the rheumatic
ause, we believe that young rheumatic patients deserve the
enefit of the Ross II operation, because the alternative
mechanical or bioprosthetic mitral replacement) is not en-
irely satisfactory.
Although approximately half of the patients with mitral
isease have concomitant atrial fibrillation, we should not
ccept a mechanical option because the risk of thromboem-
olism is much higher from the mechanical prosthesis than
rom lone atrial fibrillation, and there are fairly effective
ethods of atrial fibrillation ablation currently available.
The pulmonary autograft has unique salutary features,
hief among which is its viability and nonthrombogenicity.
ts stentless design also keeps mitral gradients at a minimum
nd accommodates the mitral annulus in the changes of the
ardiac cycle. Its ability to grow with the child is yet to be
roven, as well as its long-term durability, both of which
eed longer follow-ups.
We believe that there is a place for the mitral pulmonary
utograft in the cardiac surgeon’s armamentarium. We see a
lear benefit for it in the difficult congenital mitral lesion
hat cannot be repaired23 and in those patients who cann
ake anticoagulants and have a long life expectancy ahead of
hem. It should be seriously considered in developing areas
f the world where lifelong anticoagulation is not practical
ut where pulmonary homografts can somehow be ob-
ained. It is unfortunate that only a few teams in the world
ave been willing to adopt the procedure.6,20,23-26
We think the best candidates for the Ross II operation are
hose who are in sinus rhythm, are aged less than 50 years,
ave a large enough left atrium (5 cm), and have no
mportant comorbid conditions.
ber 2007
R1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
D
D
e
w
o
a
s
u
t
p
p
s
t
p
w
t
t
t
W
T
r
t
u
m
p
w
g
p
a
p
o
h
w
A
t
a
p
w
s
a
q
t
t
i
a
B
s
Kabbani et al Surgery for Acquired Cardiovascular Disease
A
CDeferences
1. Kabbani SS, Ross DN, Jamil H, et al. Mitral valve replacement with
pulmonary autograft- initial experience. J Heart Valve Dis. 1999;8:
359-67.
2. Kouchoukos NT, Masetti P, Nickerson NJ, et al. The Ross procedure:
long-term clinical and echocardiographic follow-up. Ann Thorac Surg.
2004;78:773-81.
3. Carpentier A. Cardiac valve surgery—the “French correction.” J Tho-
rac Cardiovasc Surg. 1983;86:323-37.
4. Kabbani SS, Jamil H, Hammoud A. Technique for replacing the mitral
valve with a pulmonary autograft: the Ross-Kabbani operation. Ann
Thorac Surg. 2001;72:947-50.
5. Kabbani S, Jamil H, Murad GH, Hamzeh KH, Sabbagh A. Ablation of
atrial fibrillation using microwave energy—early experience. Asian
Cardiovasc Thorac Ann. 2005;13:247-50.
6. Hubka M, Siska K, Holec V. Replacement of the mitral valve with an
aortic valve homograft implanted into the left atrium. J Thorac Car-
diovasc Surg. 1967;53:260-7.
7. Kabbani SS, Jamil H, Hammoud A, Nabhani F, Hariri R, Sabbagh N.
The mitral pulmonary-autograft: a follow-up cautionary report.
J Heart Valve Dis. 2000;9:801-4.
8. Kabbani S, Jamil H, Hammoud A, et al. Use of the pulmonary
autograft for mitral replacement—short and medium-term experience.
Eur J Cardiothorac Surg. 2001;20:257-61.
9. Kabbani S, Jamil H, Hammoud A, et al. The mitral pulmonary-
autograft: assessment at midterm. Ann Thorac Surg. 2004;78:60-5.
0. Yacoub MH, Kittle CF. A new technique for replacement of the mitral
valve by a semilunar valve homograft. J Thorac Cardiovasc Surg.
1969;58:859-69.
1. Kabbani SS. Editorial: is an optimal mitral substitute within reach?
Ann Thorac Surg. 2000;69:1651-2.
2. Kabbani S. Is it time to look for an alternative? Asian Cardiovasc
Thorac Ann. 2001;9:79-81.
3. Chauvaud S, Waldmann T, d’Attellis N, et al. Homograft replacement
of the mitral valve in young recipients: mid-term results. Eur J Car-
diothorac Surg. 2003;23:560-6.
4. Mohr FW, Lehmann S, Falk V, et al. Clinical experience with stentless
mitral valve replacement. Ann Thorac Surg. 2005;79:772-5.
5. Antunes MJ, Med M, Santos LP. Performance of glutaraldehyde-
preserved porcine bioprosthesis as a mitral valve substitute in a young
population group. Ann Thorac Surg. 1984;37:387.
6. Jamieson E, Marchand M, Pelletier C, et al. Structural valve deterio-
ration in mitral replacement surgery: comparison of Carpentier-Ed-
wards supra-annular porcine and Perimount pericardial bioprostheses.
J Thorac Cardiovasc Surg. 1999;118:297-305.
7. Borger MA, Ivanov J, Armstrong S, Christie-Hrybinsky D, Fiendel
CM, David TE. Twenty-year results of the Hancock II bioprosthesis.
J Heart Valve Dis. 2006;15:49-56.
8. Kirali K, Güler M, Tuncer A, et al. Fifteen-year clinical experience
with the Biocor porcine bioprostheses in the mitral position. Ann
Thorac Surg. 2001;71:811-5.
9. Ross DN, Kabbani S. Mitral valve replacement with a pulmonary
autograft: the mitral top hat. J Heart Valve Dis. 1997;6:542-5.
0. Steer AC, Carapetis JR, Nolan RM, Shann F. Systematic review of
rheumatic heart disease prevalence in children in developing countries:
the role of environmental factors. J Paediatr Child Health. 2002;38:
229-34.
1. Al-Halees Z, Pieters F, Qadoura F, Shahid M, Al-Amri M, Al-Fadley
F. The Ross procedure is the procedure of choice for congenital aortic
valve disease. J Thorac Cardiovasc Surg. 2002;123:437-42.
2. Kumar A, Talwar S, Saxena A, Singh R. Ross procedure in rheumatic
aortic valve disease. Eur J Cardiothorac Surg. 2006;29:156-61.
3. Frigiola A, Badia T, Ponie G, et al. Pulmonary autograft for mitral
valve replacement in infants: the Ross-Kabbani operation. Ann Thorac
Surg. 2005;79:2150-1.
4. Kumar AS, Aggarwal S, Choudhary SK. Mitral valve replacement
with the pulmonary autograft: the Ross II procedure. J Thorac Car-
diovasc Surg. 2001;122:378-9.
5. Brown JW, Ruzmetov M, Turrentive MW, Rodefeld MD. Mitral valve
replacement with the pulmonary autograft: Ross II procedure with h
The Journal of ThoracicKabanni modification. Semin Thorac Cardiovasc Surg Pediatr Card
Surg Annu. 2004;7:107-14.
6. Athanasiou T, Cherian A, Ross D. The Ross II procedure: pulmonary
autograft in the mitral position. Ann Thorac Surg. 2004;78:1489-95.
iscussion
r J. Brown (Indianapolis, Ind): Your experience with this op-
ration is clearly the largest and the best in the world. Mr Ross,
ho is credited with this operation, did the autograft replacement
f the mitral valve in 8 patients before the 2 of you collaborated,
nd then you have continued to modify his technique to make it
impler and more reproducible. The pulmonary autograft has been
sed in thousands of patients in the aortic valve position but in less
han 150 patients in the mitral position. The autograft is the only
otential durable bioprosthetic valve that is available for the mitral
osition. As a congenital heart surgeon, I use this operation for a
elect group of patients who cannot be treated with other alterna-
ives. We have had excellent results in our small series of 8
atients with the pulmonary autograft, except in 2 or 3 patients in
hom unacceptable mitral regurgitation developed because 1 of
he leaflets stretched.
Do you aggressively treat systemic hypertension in your pa-
ients postoperatively to prevent stretching of the pulmonary au-
ograft leaflets until they adapt to left ventricular systolic pressure?
hat is your graft material of choice to support your autograft?
he woven Dacron graft that we have used in the United States has
ecently been discontinued. So we are looking for a woven graft
hat is stiff enough. How would you select the graft size? Do you
se preoperative echo? And if you do use preoperative echo, how
uch larger a graft do you select than the echo diameter of the
ulmonary autograft? And fourth, have the 2 children who under-
ent this technique and had the grafts split shown evidence of
rowth of their autograft?
Dr Kabbani: Yours has been one of the few teams who have
icked up this procedure and have been supportive of our endeavor
ll along.
We have had no problem with the pulmonary hypertensive
atients. For some reason after the operation, after any operation,
n a stenotic valve, the pulmonary pressure just decreases, and we
ave not had any reason to deal with these patients in a special
ay.
As far as the graft material is concerned, we have used Dacron.
s you say, when we started using the newer soft variety, we had
his problem, and we reverted to autoclaving the material with
lbumin, hoping to get some resilience; however, in another 2
atients the problem recurred, probably because the albumin was
ashed away with warm blood. So now what we are doing is very
ecure, and that is using BioGlue between the pericardium sleeve
nd the Dacron material. This makes the substance of the conduit
uite firm, and we have had no problem since.
In regard to the sizing of the graft, we take the eyeball sizing of
he pulmonary artery and we take a size that is just slightly larger
han that. We have had no problem with the sizing at all, and this
s one thing that we don’t have to worry about in this operation.
Of the 2 children, 1 had endocarditis and we had to explant the
utograft a few years after the operation, and 1 is okay; he is in
eirut, but the family will not bring him in to have another echo
o that we can know that the valve grew with the child. So I don’t
ave an answer to your last question.
and Cardiovascular Surgery ● Volume 134, Number 4 907
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A
CDDr P. Granados (Malaga, Spain): Congratulations on your
ork, Dr Kabbani. What is the fate of the homograft in these
atients, because we didn’t see any data? Did you take any
harmacologic measures to prevent homograft deterioration?
Dr Kabbani: You are talking about the pulmonary homografts,
he homografts in the pulmonary position? Yes, we have 4 patients
ho are starting to show stenosis; only 1 is critical and needs an
peration, but we have not operated on any of them yet.
No, we don’t give any special treatments, so far we have not
one so, to prevent stenosis in the pulmonary homografts.
Dr M. del Rio (Riverside, Calif): Insofar as the autograft, I
ave toyed around with a hybrid valve for which one uses 2 leaflets
f the pulmonary valve and retains 1 of the leaflets of the mitral
alve and insets that into the mitral position. Has that ever been
ried at your institution or tested in that way?
Dr Kabbani: No.
Dr del Rio: All right.
Dr J. Fragata (Lisbon, Portugal): I was always a bit reluctant
o perform the Ross operation in patients with rheumatic fever or
history of rheumatic fever. Do you have any evidence or idea
hether the rheumatic process can continue in the autograft valve
n the mitral position and would you keep these patients on
ntirheumatic prophylaxis?
Do you anticoagulate these patients? When we perform a
ontan operation with a lateral tunnel, sometimes some clots go
round the prosthetic tube. I know this is covered with pericar-
ium, but don’t you get any clots around the tube in the floor of the
trium, around the annulus of the mitral valve? r
08 The Journal of Thoracic and Cardiovascular Surgery ● OctoDr Kabbani: The first question was regarding rheumatic ac-
ivity, and we expect that what we will have with the mitral
ulmonary autograft is similar to what was experienced by those
ho did the classic Ross in the aortic position. Dr Al-Halees from
audi Arabia reported in his rheumatic series that approximately
0% of his patients had rheumatic activity in the autograft. There
as only 1 patient in whom we suspected that there was rheumatic
nvolvement in the pathology, but that was all in this series.
As for the second question, you are right, theoretically you
ight have clots in that area between the autograft and the left
trium, but we have had no problem from there. We anticoag-
late these patients for 3 months for a start, and then we stop if
he patient is in sinus rhythm. We anticoagulate them if they are
n atrial fibrillation for an international normalized ratio of 2 or
.5.
Dr S. Yassin (Albuquerque, NM): How do you address the 4
atients in whom the autograft had to be sacrificed?
Dr Kabbani: I am sorry, I don’t understand the question.
Dr Yassin: You mentioned there were 4 patients in whom the
utograft could not be used. How did you address those patients?
Dr Kabbani: What did I do?
Dr Yassin: Yes.
Dr Kabbani: We just used a mechanical prosthesis instead. We
xplanted them because there was a bent conduit causing obstruc-
ion. In 2 patients, we could do something about it; I don’t want to
ake the time of the audience, but the 4 that we sacrificed were
eplaced with a mechanical prosthesis.
ber 2007
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CDFigure E1. Distribution of patients according to 10-yea
in each age group are presented.r age groups; the total number of patients and percentagesThe Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 4 908.e1
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A
CDFigure E2. Stages of operation. A, Flap of pericardium 10 cm long is created and left hanging until a decision is
made to perform operation. B, If mitral reconstruction is impossible and a Ross II operation is decided on, a 10 
4 cm of pericardium (in the adult patient) is excised. C, Pulmonary autograft is taken down as in the classic Ross
operation. D, Pulmonary substitute (preferably a pulmonary homograft) is interposed. E, A 2.5-cm piece from a
crimped woven (preferably rigid) Dacron tubing (usually 30 mm in diameter) is cut off and marked at both ends with
6 equidistant points, starting with the prefabricated line. F, Pericardial strip is wrapped around the Dacron tubing
(smooth surface out), and an adhesive glue is applied to its inner surface. G, Excess pericardium is cut off to adjust
the length and height of the pericardial strip to the Dacron tubing. H, Autograft is cleaned of fatty tissue and
trimmed down to 2 mm beyond the commissures distally and down to 2 mm of ventricular muscle proximally.08.e2 The Journal of Thoracic and Cardiovascular Surgery ● October 2007
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CDFigure E2. (Continued)The Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 4 908.e3
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A
CDFigure E2. I, Prepared autograft is inserted within the Dacron tubing, and its distal (pulmonary) end is anchored
to the Dacron pericardial tube with 3 temporary 4-0 polypropylene sutures. J, Similar procedure is done with the
proximal (ventricular) end of the autograft. K, A 5-0 polytetrafluorethylene running stitch is applied distally joining
the autograft and Dacron/pericardial conduit, removing stay sutures as they are reached. L, Distal running suture
is complete. A similar procedure is carried out proximally, in effect completing the preparation of the conduit and
covering all Dacron material. M, Distal end of the prepared conduit is sutured to the annulus of the excised mitral
valve after preserving the subvalvular apparatus as much as possible, applying some form of atrial fibrillation
ablation if necessary, and excluding the left atrial appendage. N, Schematic profile of the operation.08.e4 The Journal of Thoracic and Cardiovascular Surgery ● October 2007
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A
CDFigure E2. (Continued)Figure E3. A, Postoperative 4-chamber view echocardiogram of the autograft/Dacron conduit. B, Two-dimensional
echocardiogram with color Doppler during systole and diastole.The Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 4 908.e5
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CDFigure E4. Comparative actuarial curves for freedom from reoperation.Figure E5. Comparative actuarial survival curves.08.e6 The Journal of Thoracic and Cardiovascular Surgery ● October 2007
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CDABLE E1. Preoperative data: Clinical presentation
No. of patients
YHA I 3
YHA II 39
YHA III 42
YHA IV 4
otal 88
cho/Doppler data
ignificant leaflet
alcification 37 patients Mean
F 46%–84% 60.15 15.45
stimated PA
ystolic pressure
27–90 mm Hg 46.65 13
A 3.5–9.2 cm 6.03 1.5
VA (for MS) 0.5–1.9 cm2 1.14 0.4 cm2
YHA, New York Heart Association; EF, ejection fraction; PA, pulmonary
rtery; LA, left atrium; MVA, mitral valve area; MS, mitral stenosis.
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EABLE E2. Operative data
No. of patients
ransseptal approach 33
tandard left atriotomy 55
VO reconstructed with:
Pulmonary homograft 29
Pulmonary xenograft 56 Size: 21–30 (mean 25)
Aortic homograft 3
ricuspid annuloplasty 26
F ablation therapy with
microwave
11
ericardial sleeve 46
“Top-hat” configuration 36
“Mini-skirt” configuration 10
ree Dacron tubing 42
ortic crossclamp time 92–275 min (mean
124.97 34 min)VO, Right ventricular outflow; AF, atrial fibrillation. m
The Journal of Thoracic aABLE E3. Echo/Doppler data on discharge from hospital
VA 1.8–4.9 cm2
(mean 2.97 0.53)
ean mitral gradient 2–9 mm Hg
(mean 3.5 1.45)
A systolic pressure 12–60 mm Hg
(mean 27.4 9.5)
No. of patients
ild paravalvular leak 3
MR 57
race MR 19
ild TR 7
VA, Mitral valve area; MR, mitral regurgitation; TR, tricuspid regurgita-ABLE E4. Review of 64 patients’ follow-up
YHA Class: I 44 patients
Class: II 18 patients
Class: III 2 patients
Class: IV 0 patients
hythm: Sinus 39 patients (61%)
AF 25 patients
nticoagulation No 42 patients (66%)
Yes 22 patients
YHA, New York Heart Association. Excluding fatalities, lost to follow-up,ABLE E5. Review of 64 patients’ echocardiograms
VA (mean 3.05 0.51)
 median  3
itral gradient (mean 5.28 1.99)
 median  5
18 patients
ild 39 patients
ild to moderate 4 patients
oderate 3 patients
R
ild 41 patients
ild to moderate 6 patients
oderate 10 patients
evere 7 patients
A systolic pressure 12–48 mm Hg (mean 28.8 16.7)
 median  32.5
A peak gradient 5–64 mm Hg (mean 11.04 4.61)
 median  11.3
VA, Mitral valve area; TR, tricuspid regurgitation; PA, pulmonary artery.
xcluding fatalities, lost to follow-up, and explants. Last outpatient depart-
ent visit.
nd Cardiovascular Surgery ● Volume 134, Number 4 908.e7
